Contraception
Volume 77, Issue 2 , Pages 122-129 , February 2008

Differentiating normal from abnormal rates of genital epithelial findings in vaginal microbicide trials

  • Janneke H.H.M. van de Wijgert

      Affiliations

    • Academic Medical Center, Center for Poverty-related Communicable Diseases, P.O. Box 22700, 1100 DE Amsterdam, The Netherlands
    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA
    • Corresponding Author InformationCorresponding author. Academic Medical Center, Center for Poverty-related Communicable Diseases, PO Box 22700, 1100 DE Amsterdam, The Netherlands. Tel.: +31 20 5663044.
    • ,
  • Peter H. Kilmarx

      Affiliations

    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA
    • National Center for HIV, STD and TB Prevention, Centers for Disease Control and Prevention, Atlanta, GA 0333, USA
    • ,
  • Heidi E. Jones

      Affiliations

    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA
    • Department of Ob/Gyn, Columbia University Medical Center, New York, NY 10032, USA
    • ,
  • John M. Karon

      Affiliations

    • Emergint Corp., Louisville, KY 40206, USA
    • ,
  • Supaporn Chaikummao

      Affiliations

    • Population Council, One Dag Hammerskjold Plaza, New York, NY 10017, USA

Received 23 August 2007 ,Accepted 15 October 2007.

References 

  1. Alliance for Microbicide Development. Microbicide Research and Development Database (MRDD). Silverspring (Md). Alliance for Microbicide Development. At: http://www.microbicide.org.html.Accessed on August 21, 2007.
  2. Miller CJ, Shattock RJ. Target cells in vaginal HIV transmission. Microbes Infect. 2003;5:59–67
  3. World Health Organization . Manual for the standardization of colposcopy for the evaluation of vaginally administered products: an update. Geneva, Switzerland: WHO; 2000;
  4. Bollen L, Kilmarx PH, Wiwatwongwana P. Photo atlas for microbicide evaluation. Bangkok, Thailand: Thailand MOPH — U.S. CDC Collaboration; 2002;
  5. Fraser IS, Lahteenmaki P, Elomaa K, et al. Variations in vaginal epithelial surface appearance determined by colposcopic inspection in healthy, sexually active women. Reprod. 1999;14:1974–1978
  6. van Damme L, Niruthisard S, Atisook R, et al. Safety evaluation of nonoxynol-9 gel in women at low risk of HIV infection. AIDS. 1998;12:433–437
  7. Roddy RE, Cordero M, Cordero C, Fortney JA. A dosing study of nonoxynol-9 and genital irritation. Internat J STD AIDS. 1993;4:165–170
  8. Stafford MK, Ward H, Flanagan A, et al. Safety study of nonoxynol-9 as a vaginal microbicide: evidence of adverse effects. J Acquir Immune Defic Syndr. 1998;17:327–331
  9. Van Damme L, Wright A, Depraetere K, et al. A phase I study of a novel potential intravaginal microbicide, PRO 2000, in healthy sexually inactive women. Sex Transm Inf. 2000;76:126–130
  10. van de Wijgert J, Fullem A, Kelly C, et al. Phase 1 trial of the topical microbicide BufferGel: safety results from four international sites. J Acquir Immune Defic Syndr. 2001;26:21–27
  11. Mauck CK, Weiner DH, Ballagh S, et al. Single and multiple exposure tolerance study of cellulose sulfate gel: a Phase 1 safety and colposcopy study. Contraception. 2001;64:383–391
  12. Low-Beer N, Gabe R, McCormack S, Kitchen VS, Lacey CJ, Nunn AJ. Dextrin sulfate as a vaginal microbicide: randomized, double-blind, placebo-controlled trial including healthy female volunteers and their male partners. J Acquir Immune Defic Syndr. 2002;31:391–393
  13. Ballagh SA, Baker JM, Henry DM, Archer DF. Safety of single daily use for one week of C31G HEC gel in women. Contraception. 2002;66:369–375
  14. Mayer KH, Karim SA, Kelly C, et al. for the HIV Prevention Trials Network (HPTN) 020 protocol team Safety and tolerability of vaginal PRO 2000 gel in sexually active HIV-uninfected and abstinent HIV-infected women. AIDS. 2003;17:321–329
  15. Mauck CK, Weiner DH, Creinin MD, Barnhart KT, Callahan MM, Bax R. A randomized phase I vaginal safety study of three concentrations of C31G vs. extra strength I.I. Gynol. Contraception. 2004;70:233–240
  16. El-Sadr WM, Mayer KH, Maslankowski L, et al. for the HIV Prevention Trials Network (HPTN) 049 protocol team Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006;20:1109–1116
  17. Mayer KH, Maslankowski L, Gai F, et al. and the HPTN 050 protocol team Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543–551
  18. Jespers VA, Van Roey JM, Beets GI, Buvé AM. Dose-ranging Phase I study of TMC120, a promising vaginal microbicide, in HIV-negative and HIV-positive female volunteers. J Acquir Immune Defic Syndr. 2007;44:154–158
  19. Kilmarx P, van de Wijgert J, Chaikummao S, et al. Safety and acceptability of the candidate microbicide Carraguard in Thai women: findings from a Phase II clinical trial. J Acquir Immune Defic Syndr. 2006;43:327–334
  20. Coggins C, Blanchard K, Alvarez F, et al. Preliminary safety and acceptability of a carrageenan gel for possible use as a vaginal microbicide. Sex Transm Infect. 2000;76:480–483
  21. Maguire RA, Bergman N, Phillips DM. Comparison of microbicides for efficacy in protecting mice against vaginal challenge with herpes simplex virus type 2, cytotoxicity, antibacterial properties, and sperm immobilization. Sex Transm Dis. 2001;28:259–265
  22. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29:297–301
  23. Young NL, Kilmarx PH, Borchardt K, Chaowanachan T, Wasinrapee P, Suksripanich O. Inhibitory effects of vaginal microbicides on COBAS Amplicor and Gen-Probe Chlamydia trachomatis and Neisseria gonorrhoeae, and InPouch Trichomonas vaginalis tests. [Abstract] Int J STD AIDS. 2001;12(Suppl 2):193
  24. Hardin JW, Hilbe JM. Generalized estimating equations. Boca Raton (Fl): Chapman and Hall/CRC; 2003;
  25. Therneau TM, Grambsch PM. Modeling survival data: Extending the Cox model. New York: Springer; 2000;
  26. Lincoln C. Sexual injury: is it significant? A review of the literature. Med Sci Law. 2001;41:206–216
  27. Eschenbach DA, Patton DL, Hooton TM, et al. Effects of vaginal intercourse with and without a condom on vaginal flora and vaginal epithelium. J Infect Dis. 2001;183:913–918
  28. Georgijevic AV, Sisovic JR, Djukic SV, Bujko MJ. Colposcopic and cytologic findings among women with abnormal vaginal flora. J Low Genit Tract Dis. 2002;6:155–161
  29. Galhardo CL, SoaresJr JM, Simoes RS, Haidar MA, Rodrigues de Lima G, Baracat EC. Estrogen effects on the vaginal pH, flora and cytology in late postmenopause after a long period without hormone therapy. Clin Exp Obstet Gynecol. 2006;33:85–89
  30. Fichorova RN. Guiding the vaginal microbicide trials with biomarkers of inflammation. J Acquir Immune Defic Syndr. 2004;37(Suppl 3):S184–S193
  31. Moench T. Sensitive methods to detect epithelial disruptions: tests for microhemorrhage in cervicovaginal lavages. J Acquir Immune Defic Syndr. 2004;37(Suppl 3):S194–S200

☆ None of the authors have a commercial association with Carraguard nor other conflicts of interest. Carraguard is being developed by the Population Council, which is a not-for-profit nongovernmental organization, under a US Food and Drug Administration Investigational New Drug Application (IND 58,441). Financial support for this study was provided by the US Centers for Disease Control and Prevention and the Bill and Melinda Gates Foundation. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the US Centers for Disease Control and Prevention.

PII: S0010-7824(07)00460-X

doi: 10.1016/j.contraception.2007.10.006

Contraception
Volume 77, Issue 2 , Pages 122-129 , February 2008

Article Tools

* Image Usage & Resolution